Navigation Links
Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results
Date:11/4/2009

SAN DIEGO, Nov. 4 /PRNewswire-FirstCall/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced unaudited financial results for the three months ended September 30, 2009.

Three Months Ended September 30, 2009

As of September 30, 2009, Orexigen held $56.9 million in cash and cash equivalents and an additional $50.9 million in investment securities, available-for-sale. Together, these amounts total $107.8 million.

For the three months ended September 30, 2009, Orexigen reported a net loss of $14.4 million, or $0.33 per share attributable to common stockholders, compared to a net loss of $24.8 million, or $0.72 per share attributable to common stockholders, for the comparable period in 2008.

Total operating expenses for the three months ended September 30, 2009, were $14.2 million compared to $25.1 million for the comparable period in 2008. The decreased operating expenses were due primarily to a decrease in research and development expenses in connection with the completion of the Company's Contrave® Phase 3 clinical trials, related proprietary product formulation work and consulting activities totaling approximately $12.9 million. The decrease was partly offset by an increase in costs incurred in connection with the preparation of the Contrave NDA and an increase in salaries and personnel related costs. In addition, general and administrative expenses increased approximately $1.0 million due primarily to an increase in salaries and personnel related costs, legal and accounting fees, recruiting expense and facilities costs.

"The recent completion of the COR Phase 3 program and the Phase 2b trial of Empatic(TM) were major milestones for Orexigen," said Mike Narachi, President and CEO of Orexigen. "The
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
2. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
3. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
4. Orexigen(R) Therapeutics Schedules July 20, 2009 Teleconference and Webcast Discussion of Contrave(R) Phase 3 Results
5. Orexigen(R) Therapeutics Schedules September 30, 2009 Teleconference and Webcast to Discuss Phase 2b Trial Results From Second Obesity Drug Candidate, Empatic(TM)
6. Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society
7. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
8. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
11. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... N.J., July 30, 2015 PTC Therapeutics, Inc. ... and reported financial results for the second quarter ending ... on many fronts across the organization.  We are excited ... muscular dystrophy clinical trial ever conducted with topline results ... Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. "Translarna is ...
(Date:7/30/2015)... Tianyin Pharmaceutical Inc. (NYSE Amex: TPI ... the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded ... the notice it received on May 21, 2015 from ... Company was below certain of the Exchange,s continued listing ... of the NYSE MKT Company Guide, due to the ...
(Date:7/30/2015)... Eisai Inc. announced today that regulatory applications ... , European Union and Japan ... eribulin, for the treatment of patients with inoperable soft ... advanced or metastatic disease. These regulatory ... Phase 3 clinical trial (Study 309), which met its ...
Breaking Medicine Technology:PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5
...   SAP America Inc., a subsidiary of ... SAP ), today introduced the SAP® Collaborative E-Care Management application ... the application aims to connect care providers, patients and their ... at HIMSS 2012 , being held February 20–24 in ...
... SurgLine International, Inc. (SGLN.PK). Thomas Toland, ... the past six months we have made certain public ... contracts and a pending acquisition in an effort to ... Our management team has completed an internal ...
Cached Medicine Technology:Newsbyte: SAP to Integrate Healthcare in the Community Through Collaborative Care 2SurgLine International, Inc. Update to Shareholders on Revenue Pipeline and Organizational Changes 2
(Date:7/30/2015)... Church, VA (PRWEB) , ... July 31, 2015 ... ... Manufacturing Floor:, Reduce Errors By 50% or More, **Presented by FDAnews and Ginette ... Dr. Ginette Collazo, a 15 year veteran of helping drug, biologic and device ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... products, announces I am Fine, an app invention that can help people during ... 2017," says Scott Cooper, CEO and Creative Director of World Patent Marketing. "Currently, ...
(Date:7/30/2015)... ... ... In an effort to provide the twenty four hour continuous care desired by his ... The decision will also allow him to spend more time in the office with ... to the hospitalists at East Liverpool City Hospital.Dr. Aggarwal has always provided excellent care ...
(Date:7/30/2015)... CATHERAL CITY, California (PRWEB) , ... July 30, 2015 , ... ... of substance abuse, clients at Serenity Palms Drug Addiction Treatment Center have created an ... Springs just lost one of its most beloved residents, Rocky Hudson . Hudson ...
(Date:7/30/2015)... ... ... Google recently announced that it will be disclosing any incidents involving its ... 8, 2015 article published by Nasdaq , the powerful tech company maintains that ... cars, which such industry players as Tesla CEO Elon Musk believe may very well ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 2Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 3Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 4Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 2Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 3Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 4Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 5Health News:River Valley Physician Dr. Aggarwal is Making Changes to his Practice 2Health News:Serenity Palms Honors Rocky Hudson, an Advocate of AA and a Beloved Resident of Palm Springs 2Health News:Serenity Palms Honors Rocky Hudson, an Advocate of AA and a Beloved Resident of Palm Springs 3Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 2Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 3
... During Pregnancy; Infants Should Undergo Oral Health Assessment by ... The American Academy of Pediatric Dentistry (AAPD), the ... health guidelines for expectant mothers and infants following its ... for all pregnant women to receive counseling and oral ...
... Total Could Include Millions More , , WASHINGTON, June 10 ... every seven -- will receive a smaller Social Security check next ... (TSCL). Millions of other seniors who do not have their Medicare ... Security dollars leftover next year. , , These seniors ...
... Ill., June 10 To fulfill an increasing demand for ... opened a new branch location in the Prologis Business Park ... a class start in July 2009. , , ... The program is 750 hours in length (56 quarter credits) ...
... Long-Acting Injection in Development , , WASHINGTON and CHADDS FORD, ... from low testosterone saw two or more doctors before the condition ... they stopped taking their medicine, according to results of a survey ... than 100 men who had been diagnosed with and treated for ...
... an Outrage to Older Americans , , WASHINGTON, June ... President Obama and his Congressional allies for proposing to cut ... care reform." Thair Phillips, the new president of RetireSafe, ... , , Said Phillips, "I,m outraged that President Obama ...
... when teens are efficient sleepers, study finds, , WEDNESDAY, June ... sleep just might lead to higher grades, especially in math. ... teens, ages 14 to 18, who had complained of insufficient ... of the participants, and the teens provided information on their ...
Cached Medicine News:Health News:American Academy of Pediatric Dentistry Releases New Perinatal and Infant Oral Health Guidelines 2Health News:American Academy of Pediatric Dentistry Releases New Perinatal and Infant Oral Health Guidelines 3Health News:American Academy of Pediatric Dentistry Releases New Perinatal and Infant Oral Health Guidelines 4Health News:One in Seven Seniors Faces Social Security Check Cuts in 2010 2Health News:Cortiva Institute to Open Branch Location in Woodridge, IL 2Health News:Men with Low Testosterone See Multiple Doctors Before Being Diagnosed; Many Dissatisfied with Current Treatment Options 2Health News:Men with Low Testosterone See Multiple Doctors Before Being Diagnosed; Many Dissatisfied with Current Treatment Options 3Health News:Men with Low Testosterone See Multiple Doctors Before Being Diagnosed; Many Dissatisfied with Current Treatment Options 4Health News:Men with Low Testosterone See Multiple Doctors Before Being Diagnosed; Many Dissatisfied with Current Treatment Options 5Health News:Men with Low Testosterone See Multiple Doctors Before Being Diagnosed; Many Dissatisfied with Current Treatment Options 6Health News:RetireSafe Blasts Plan to Pay for Health Care Reform With Huge Medicare Cuts 2Health News:As Sleep Improves, Grades Seem to Go Up 2
Specially designed wider jaws to help split soft nucleus, cross action, round handle, maximum opening 2.8 mm....
Cross action, round handle, maximum opening 2.8 mm....
Dodick nucleus cracker cross-action longitudinally serrated paddle shaped jaws for cracking the nucleus through a 3.0 mm incision....
Irrigating nucleus chopper, 1.5 mm long wedge-shaped, inferior edge with round end, 0.6 mm dual sideports 20 gauge....
Medicine Products: